TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29427913

Group type: EXPERIMENTAL
Intervention: l-carnosine (2 gr/day in two divided doses)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 26913539

Group type: EXPERIMENTAL
Intervention: Larger group size (more academic authors or MBA students)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit consideration of others' contributions
Number of subjects: 0
Study: 25526495

Group type: EXPERIMENTAL
Intervention: Artificial liver support system (ALSS) plus standard medical therapy (SMT), n = 104
Number of subjects: 234

Group type: COMPARATOR
Intervention: Standard medical therapy (SMT) alone, n = 130
Number of subjects: 234
Study: 21800218

Group type: EXPERIMENTAL
Intervention: Resistance to empiric therapy for gram positive cocci and coliforms
Number of subjects: 229

Group type: EXPERIMENTAL
Intervention: Presence of only gram positive cocci, predominantly Enterococcus spp.
Number of subjects: 229
Study: 18665360

Group type: EXPERIMENTAL
Intervention: Rituximab maintenance therapy (8 cycles of 375 mg/m² every 3 months)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 122
Study: 17242421

Group type: EXPERIMENTAL
Intervention: Self-reported medication adherence
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported medication adherence <80%
Number of subjects: 0
Study: 15648727

Group type: EXPERIMENTAL
Intervention: Arabic or Mandarin numerals naming, adding, or multiplying
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnitude comparisons on pairs of Arabic or Mandarin numerals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory for arithmetic facts
Number of subjects: 0
Study: 12353898

Group type: EXPERIMENTAL
Intervention: Combined resection and anterior transposition of the inferior oblique muscle
Number of subjects: 9
Study: 10449017

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (25 g x d(‐1) for 1 week followed by 5 g x d(‐1) for 11 weeks)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 8526758

Group type: EXPERIMENTAL
Intervention: Arrhythmogenic zones
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-arrhythmogenic zones
Number of subjects: 0
Study: 2085577

Group type: EXPERIMENTAL
Intervention: Povidone iodine and nonocclusive dressings changed 2 to 3 times weekly
Number of subjects: 127

Group type: COMPARATOR
Intervention: Nondisinfectant soap and water
Number of subjects: 127
Study: 158569

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide gel 2.5%
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide gel 5%
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide gel (both strengths)
Number of subjects: 200
Study: 6805715

Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg
Number of subjects: 26

Group type: COMPARATOR
Intervention: Pethidine 100 mg
Number of subjects: 26
Study: 31973735

Group type: EXPERIMENTAL
Intervention: Fluid responsiveness assessment (FR+ vs FR-)
Number of subjects: 348

Group type: COMPARATOR
Intervention: Fluid administration
Number of subjects: 348
Study: 30598384

Group type: EXPERIMENTAL
Intervention: Farmed Atlantic salmon consumption (3 times weekly for 16 weeks)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Meat consumption (3 times weekly for 16 weeks)
Number of subjects: 205
Study: 28759113

Group type: EXPERIMENTAL
Intervention: EN-DUR (exercise and nutrition intervention during RT)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: EN-AF (exercise and nutrition intervention after RT)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Comparison between EN-DUR and EN-AF
Number of subjects: 41
Study: 27579824

Group type: EXPERIMENTAL
Intervention: Act on Threes educational intervention combined with standard care
Number of subjects: 6243

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 6243
Study: 24929782

Group type: EXPERIMENTAL
Intervention: Association Splitting (AS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Computerized cognitive training
Number of subjects: 70
Study: 22709616

Group type: EXPERIMENTAL
Intervention: Group Metacognitive Training (MCT)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 19
Study: 19322115

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol releasing 0.014 mg estradiol (E2)/week
Number of subjects: 270

Group type: COMPARATOR
Intervention: Raloxifene hydrochloride 60 mg/day
Number of subjects: 270
Study: 17574455

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15095035

Group type: EXPERIMENTAL
Intervention: Milk powder equivalent to 1300 mg calcium
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Milk powder equivalent to 650 mg calcium
Number of subjects: 344

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 344
Study: 11822993

Group type: EXPERIMENTAL
Intervention: Oral cocaine 150 mg
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Oral cocaine 200 mg
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 10078487

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 264

Group type: COMPARATOR
Intervention: Control (meningococcal vaccine, pneumococcal vaccine, or placebo)
Number of subjects: 264
Study: 8788313

Group type: EXPERIMENTAL
Intervention: 200 micrograms octreotide
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 2251976

Group type: EXPERIMENTAL
Intervention: 50 mg BCH 069 (intravenous injection) 3 times weekly for 6 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 50 mg BCH 069 (subcutaneous injection) 3 times weekly for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injection) 3 times weekly for 4 weeks
Number of subjects: 0
Study: 6103755

Group type: EXPERIMENTAL
Intervention: Oxyprothepin decanoate
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluphenazin decanoate
Number of subjects: 30
Study: 31162787

Group type: EXPERIMENTAL
Intervention: Tapentadol sustained-release
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 28939607

Group type: EXPERIMENTAL
Intervention: Mupirocin-based decolonization therapy
Number of subjects: 95

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline MRSA isolates
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 3 months follow-up MRSA isolates
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Baseline multidrug resistance (MDR)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: 3 months follow-up MDR
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rural homes
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Antimicrobial use
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Clindamycin use
Number of subjects: 95
Study: 26297296

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention in health centers
Number of subjects: 1955
Study: 23384372

Group type: EXPERIMENTAL
Intervention: 40 mg of memantine
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 20828791

Group type: COMPARATOR
Intervention: Zoledronic acid
Number of subjects: 8
Study: 20031834

Group type: EXPERIMENTAL
Intervention: Information technology‐supported management program
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 223
Study: 17163096

Group type: EXPERIMENTAL
Intervention: Adjuvant therapies including anthracycline- and taxane-based polychemotherapeutics, trastuzumab, with or without endocrine manipulation and with or without PMRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newer agents
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classic six cycles of intravenous CMF
Number of subjects: 0
Study: 15168008

Group type: EXPERIMENTAL
Intervention: Local Anesthesia (LA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 400
Study: 12098156

Group type: EXPERIMENTAL
Intervention: Arm sling
Number of subjects: 31

Group type: COMPARATOR
Intervention: No arm sling
Number of subjects: 31
Study: 11776814

Group type: EXPERIMENTAL
Intervention: Zeng Sheng Ping (ZSP)
Number of subjects: 5864

Group type: EXPERIMENTAL
Intervention: Retinamide
Number of subjects: 5864

Group type: EXPERIMENTAL
Intervention: Riboflavin
Number of subjects: 5864

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5864
Study: 7577314

Group type: EXPERIMENTAL
Intervention: DRB1*0401 and DRB1*0404 alleles
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DRB1*0101 (DR1)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DRw6 (DRB1*13,*14)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: heptapeptide motif (positions 67‐74) in the third hypervariable region
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DQA1*0301 and DQB1*0302
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DQA1*0202, DQA1*0501 and DQB1*0201
Number of subjects: 48

Group type: COMPARATOR
Intervention: DPB1 alleles
Number of subjects: 48
Study: 2182240

Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 231

Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 231
Study: 394302

Group type: EXPERIMENTAL
Intervention: 100 mg pepstatin, seven times a day
Number of subjects: 60

Group type: COMPARATOR
Intervention: 100 mg placebo, seven times a day
Number of subjects: 60
Study: 31434552

Group type: EXPERIMENTAL
Intervention: SNS intervention group (n = 23)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Education-only intervention group (n = 19)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Nonintervention group (n = 26)
Number of subjects: 68
Study: 29430794

Group type: EXPERIMENTAL
Intervention: LSAS-SR (Liebowitz Social Anxiety Scale - Self-Reported)
Number of subjects: 311

Group type: EXPERIMENTAL
Intervention: LSAS-CA (Liebowitz Social Anxiety Scale - Clinician-Administered)
Number of subjects: 311
Study: 26130486

Group type: EXPERIMENTAL
Intervention: Telephone counselling intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Telephone counselling intervention (high risk condition)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (high risk condition)
Number of subjects: 95
Study: 24812894

Group type: EXPERIMENTAL
Intervention: Comprehensive Western therapy plus blood cooling and detoxification recipe (BCDR)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Comprehensive Western therapy
Number of subjects: 105
Study: 22894746

Group type: EXPERIMENTAL
Intervention: Home self‐testing for HIV using the OraQuick ADVANCE® HIV‐1/2 Antibody Test on oral fluids
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Home self‐testing for HIV
Number of subjects: 1
Study: 20601292

Group type: COMPARATOR
Intervention: Raloxifene (60 mg and 120 mg daily combined)
Number of subjects: 0
Study: 18524598

Group type: EXPERIMENTAL
Intervention: Trained group (n=10)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Non-trained group (n=10)
Number of subjects: 20
Study: 15939067

Group type: EXPERIMENTAL
Intervention: Virgin olive oil (VOO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Refined olive oil (ROO)
Number of subjects: 40
Study: 11788467

Group type: EXPERIMENTAL
Intervention: Escherichia coli endotoxin (LPS) at doses of 1 or 2 ng/kg
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Escherichia coli endotoxin (LPS)
Number of subjects: 19
Study: 12764859

Group type: EXPERIMENTAL
Intervention: Auto CPAP treatment in UPPP group
Number of subjects: 47

Group type: COMPARATOR
Intervention: Auto CPAP treatment in untreated OSAS group
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Auto CPAP treatment in both groups
Number of subjects: 47
Study: 8671329

Group type: EXPERIMENTAL
Intervention: Acridine Orange (AO) staining of spermatozoa
Number of subjects: 103
Study: 1875221

Group type: EXPERIMENTAL
Intervention: ABM infusion after CVP
Number of subjects: 92

Group type: COMPARATOR
Intervention: NABM infusion after CVP
Number of subjects: 92
Study: 6125191

Group type: EXPERIMENTAL
Intervention: Labetalol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 31957783

Group type: EXPERIMENTAL
Intervention: Software intervention for delirium prevention
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Software usability and accessibility
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Software usage protocol
Number of subjects: 30
Study: 30893292

Group type: EXPERIMENTAL
Intervention: Everolimus with reduced-exposure calcineurin inhibitor (CNI, cyclosporine) followed by CNI withdrawal at weeks 7-11 post-transplant
Number of subjects: 95

Group type: COMPARATOR
Intervention: Standard-exposure cyclosporine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 95

Group type: COMPARATOR
Intervention: CNI
Number of subjects: 95
Study: 30517688

Group type: EXPERIMENTAL
Intervention: Average measured sodium intake (gold standard)
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: Average estimated sodium intake (using Kawasaki formula)
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: First measured sodium intake
Number of subjects: 2974

Group type: EXPERIMENTAL
Intervention: First estimated sodium intake (using Kawasaki formula)
Number of subjects: 2974
Study: 27542702

Group type: EXPERIMENTAL
Intervention: Tooth borne expander (hyrax)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study: 25216650

Group type: EXPERIMENTAL
Intervention: Anodal stimulation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cathodal stimulation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study: 21739525

Group type: EXPERIMENTAL
Intervention: Grouped lists
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ungrouped lists
Number of subjects: 0
Study: 20672956

Group type: EXPERIMENTAL
Intervention: Healos graft carrier with bone marrow aspirate and local autograft
Number of subjects: 28

Group type: COMPARATOR
Intervention: Cancellous allograft and local autograft
Number of subjects: 28
Study: 17595187

Group type: EXPERIMENTAL
Intervention: 5-MTHF (15 mg/daily for 12 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 19
Study: 16123484

Group type: EXPERIMENTAL
Intervention: Inhaled insulin (INH group)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Subcutaneous regular insulin (SC group)
Number of subjects: 47
Study: 12145478

Group type: EXPERIMENTAL
Intervention: 3,5-diiodothyropropionic acid (DITPA)
Number of subjects: 19
Study: 9989567

Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Fluphenazine
Number of subjects: 53
Study: 8548644

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1550700

Group type: EXPERIMENTAL
Intervention: Famotidine (40 mg orally)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cigarette smoking
Number of subjects: 20
Study: 3158146

Group type: COMPARATOR
Intervention: Fentanyl 0.3 mg
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Isoflurane 1-2%
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 50
Study: 29356761

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (MXF)
Number of subjects: 451

Group type: COMPARATOR
Intervention: Comparator (COMP: intravenous ertapenem followed by oral amoxicillin/clavulanate)
Number of subjects: 451
Study: 26774968

Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 17
Study: 25150638

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2916
Study: 23158059

Group type: EXPERIMENTAL
Intervention: Irradiated blood samples from radiosensitive patients (6 Gy)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Irradiated blood samples from control patients (6 Gy)
Number of subjects: 30
Study: 21245996

Group type: COMPARATOR
Intervention: Low-dose aspirin plus placebo (Placebo group)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin plus rebamipide (Rebamipide group)
Number of subjects: 10
Study: 18047518

Group type: EXPERIMENTAL
Intervention: CDP + BPO (clindamycin phosphate 10 mg mL(‐1) + benzoyl peroxide 50 mg mL(‐1))
Number of subjects: 130

Group type: COMPARATOR
Intervention: ADA (adapalene 0.1%)
Number of subjects: 130
Study: 16612303

Group type: EXPERIMENTAL
Intervention: Cultured skin substitutes (CSS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Split-thickness skin autograft (AG)
Number of subjects: 40
Study: 12860947

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 85 mg/m2 on days 1 and 15, LV 20 mg/m2 over 10 to 20 minutes, FU 500 mg/m2 bolus on days 1, 8, and 15 every 28 days
Number of subjects: 41
Study: 10853861

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (without ENDS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS) with nasal decongestant
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: External nasal dilator strip (ENDS) during voluntary hyperpnoea
Number of subjects: 20
Study: 9780094

Group type: EXPERIMENTAL
Intervention: 30% intraocular pressure reduction from baseline
Number of subjects: 145

Group type: COMPARATOR
Intervention: no treatment (control)
Number of subjects: 145
Study: 7947851

Group type: EXPERIMENTAL
Intervention: Safe Times Questionnaire (STQ) group, 79 patients
Number of subjects: 152

Group type: COMPARATOR
Intervention: Interview group, 73 patients
Number of subjects: 152
Study: 3128527

Group type: EXPERIMENTAL
Intervention: Cold air inhalation (2 degrees C)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Warm air inhalation (32 degrees C)
Number of subjects: 8
Study: 29308759

Group type: EXPERIMENTAL
Intervention: Nasointestinal tube group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nasogastric tube group
Number of subjects: 100
Study: 27283935

Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation (MiECC)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Minimally invasive extracorporeal circulation with oxygenator (MiECC+F)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Conventional extracorporeal circulation (CECC)
Number of subjects: 48
Study: 24857093

Group type: EXPERIMENTAL
Intervention: Radium-223 dichloride (Xofigo)
Number of subjects: 0
Study: 23134624

Group type: EXPERIMENTAL
Intervention: Unboosted atazanavir (ATV)
Number of subjects: 369

Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r)
Number of subjects: 369
Study: 20215934

Group type: EXPERIMENTAL
Intervention: Attachment-Based Family Therapy (ABFT)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Number of subjects: 66
Study: 18612879

Group type: EXPERIMENTAL
Intervention: Naltrexone (50 mg) for three days
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo for three days
Number of subjects: 38
Study: 15778874

Group type: EXPERIMENTAL
Intervention: Marijuana (1.8, 2.8, 3.9% THC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dronabinol (10, 20 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dronabinol (30 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Marijuana and Dronabinol
Number of subjects: 30
Study: 11803324

Group type: EXPERIMENTAL
Intervention: Normothermic CPB (rectal temperature 35‐37 degrees C, group B)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hypothermic CPB (rectal temperature 28‐32 degrees C, group A)
Number of subjects: 100
Study: 7841053

Group type: EXPERIMENTAL
Intervention: PC10 immunostaining in stage I malignant tumours
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: PC10 immunostaining in advanced ovarian cancer
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: PC10 immunostaining in patients with good debulking surgery
Number of subjects: 98
Study: 2600001

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Penicillin and netilmicin
Number of subjects: 158

Group type: COMPARATOR
Intervention: Non-treated controls
Number of subjects: 158
Study: 4969991

Group type: EXPERIMENTAL
Intervention: Phenoxymethylpenicillin (penicillin V)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Phenethicillin (Broxil)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Lincomycin (Lincocin)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 100
Study: 30730474

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 44
Study: 27923937

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration Training (WBVT)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Calisthenics training program
Number of subjects: 29
Study: 26238394

Group type: EXPERIMENTAL
Intervention: Living wage intervention including a 350% wage increase and significant workplace improvements.
Number of subjects: 204

Group type: COMPARATOR
Intervention: Minimum wage at the comparison factory.
Number of subjects: 204
Study: 23110786

Group type: EXPERIMENTAL
Intervention: Naltrexone 50 mg
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Naltrexone (5 mg and 12.5 mg)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 116
Study: 20683707

Group type: EXPERIMENTAL
Intervention: Once-weekly resistance training (n=54)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Twice-weekly resistance training (n=51)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Twice-weekly balance and tone classes (n=50)
Number of subjects: 155
Study: 19737426

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 406

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 406